<DOC>
	<DOC>NCT01452451</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and tolerability of repeated doses of HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on stable metformin monotherapy.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Is male or female and 18 to 65 years of age, inclusive, at screening Has a history of T2DM and a stable dose of metformin Has HbA1c levels at screening between 7% and 10% Is pregnant or lactating Has type 1 diabetes Has a significant change in body weight in the 3 months before screening Has a fasting plasma glucose level greater than 240 mg/dL (13.3 mmol/L) at screening Has an estimated glomerular filtration rate rate &lt;75 mL/min/1.73 m2 or has ≥75 mL/min/1.73 m2 &lt;estimated glomerular filtration rate &lt;90 mL/min/1.73 m2 with a urine albumin to urine creatinine ratio &gt;30 mg/g. Has alanine aminotransferase or aspartate aminotransferase values &gt;2.0 × upper limit of normal or total bilirubin &gt;1.5 × upper limit of normal unless the subject has a known history of Gilbert's syndrome Has fasting serum triglycerides &gt;400 mg/dL (&gt;4.52 mmol/L) or &gt;250 mg/dL (&gt;2.85 mmol/L) if not on stable lipidlowering therapy for at least 4 weeks prior to screening, or has calcitonin ≥50 ng/L. Subjects with a history of Fredrickson's Type I, IV or V hyperlipidemia will be excluded. Has any history of GI intolerance, chronic diarrhea, inflammatory bowel disease, partial bypass or gastric banding Has any acute illness within 5 days before first study drug administration Has elevated amylase, ongoing cholelithiasis, cholecystitis at screening, or history of pancreatitis Is a heavy tobacco user(more than 10 cigarettes a day) Is a heavy alcohol user Has a positive screen for drugs of abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>